Monitoring of Postoperative Residual Neuromuscular Blockade in Laparoscopic Surgery

Study Overview
=================
Brief Summary
-----------------
Compare the reversal effect of neostigmine and sugammadex using quantitative neuromuscular monitoring

Detailed Description
-----------------
At the end of surgery, decide the dosage of reversal referring to quantitative neuromuscular monitoring value (TOF). After the administration of reversal, the anesthesiologist who are going to manage the participant should not check the quantitative neuromuscular monitoring and determine the timing of extubation only with his (or her) judgement. After entering post-anaesthesia care unit (PACU) measure the TOF value and check the incidence of TOF ratio > 0.9 between the neostigmine group and sugammadex group.

Official Title
-----------------
Monitoring of Postoperative Residual Neuromuscular Blockade in Laparoscopic Surgery: Comparison of Neostigmine and Sugammadex

Conditions
-----------------
Neuromuscular Block, Residual

Intervention / Treatment
-----------------
* Drug: Neostigmine
* Drug: Sugammadex


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients aged over 18 years, planned to undergoing elective laparoscopic surgery under general anesthesia Exclusion Criteria: Obesity BMI over 30 kg/m2 Impairment of renal or/and liver function Allergy to rocuronium, sugammadex (Familial) history of malignant hyperthermia Taking medicines which is affecting neuromuscular function

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Neostigmine<br>At the end of surgery, administrating neostigmine to participants according to the protocol below: when train-of-four (TOF) 2-3, administrating neostigmine 50mcg/kg when TOF 4 with fade, administrating neostigmine 40mcg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg | Drug: Neostigmine<br>* Referring to the randomisation allocation program, participants allocated to group neostigmine, administrate neostigmine as reversal<br>|
| Active Comparator: Sugammadex<br>At the end of surgery, administrating sugammadex to participants according to the protocol below: when TOF=0 and post-tetanic count (PTC)=1 or more, administrating sugammadex 4mg/kg when TOF=1 or more, administrating sugammadex 2mg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg | Drug: Sugammadex<br>* Referring to the randomisation allocation program, participants allocated to group sugammadex, administrate sugammadex as reversal<br>* Other names: Bridion;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the incidence of postoperative residual curarization | definition of postoperative residual curarization: TOF ration is 0.9 or over 0.9 | Immediately after entering PACU |